Clinical Trial Update: Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy [Phase 1]

View source ↗

Summary

Open-label Phase 1b trial evaluating ulixertinib with cetuximab, or ulixertinib with cetuximab and encorafenib, for unresectable or metastatic colorectal cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Encorafenib (encorafenib)
• Ulixertinib (ulixertinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Colorectal Cancer | Phase 1 | Status: RECRUITING